Ganfort (201450): A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort® eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom® eye drops (tafluprost 0.0015%/timolol 0.5%).
Laufzeit: 01.01.2015 - 31.12.2016
imported
Kurzfassung
A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom eye drops (tafluprost 0.0015%/timolol 0.5%).
